Phaseline

Companies › Oscotec

Oscotec: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Immunology, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SKI-O-703 API in Capsules–Phase 1Bioequivalence Study in Healthy SubjectsDec 2026
OCT-598–Phase 1Solid TumorDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07675226SKI-O-703 API in CapsulesPhase 1Bioequivalence Study in Healthy SubjectsImmunologyDec 2026
NCT07358806OCT-598Phase 1Solid TumorOncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.